Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

BV US Equity

BrightView Holdings, Inc.Consumer Staples · Agricultural Services · CIK 1734713 · FY ends Sep 30
$11.50
+0.15 (+1.32%)
USD · as of 2026-08-18 · marketstack
3 registered studies · 0 active

Studies where BV is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

1 interventional · 2 observational

Held by 9 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, Qube Research & Technologies Ltd, D. E. Shaw & Co., Inc., AQR CAPITAL MANAGEMENT LLC, +4 more) · FINRA short interest 4.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionUpdated
A Digital Smoking Cessation Intervention for Adults With Substance Use DisorderNCT04419922observationalSmoking AbstinenceUnknown statusBehavioral: Smartphone Contingency Management InterventionTobacco Use Disorder, Substance Use Disorders1002020-10-012020-06-09
BRIDGE Device for Treatment of Opioid WithdrawalNCT04162145Comparison of change from baseline of Clinical Opiate Withdrawal Scale (COWS) scores between active BRIDGE device group and sham BRIDGE device group at one hourRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan · Informed Consent FormNot applicableTerminatedsponsor's stated reason: Due to COVID-19 pandemicDevice: Active BRIDGE device placement, Inactive BRIDGE device placementOpioid Withdrawal, Pain, Craving122020-06-23actual2020-06-25
Contingency Management Using Smartphone App in Patients With SUDNCT04162132observationalAttendanceStudy Protocol · Informed Consent FormCompletedDevice: Smartphone appSubstance Use Disorders1082019-07-29actual2019-11-20

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19